for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Vaxart Inc

VXRT.O

Latest Trade

8.22USD

Change

0.24(+3.01%)

Volume

29,654,484

Today's Range

7.62

 - 

8.43

52 Week Range

0.25

 - 

17.49

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
7.98
Open
8.10
Volume
29,654,484
3M AVG Volume
721.66
Today's High
8.43
Today's Low
7.62
52 Week High
17.49
52 Week Low
0.25
Shares Out (MIL)
107.34
Market Cap (MIL)
871.43
Forward P/E
-10.36
Dividend (Yield %)
--

Next Event

Vaxart Inc at Sachs Associates Biotech in Europe Forum (Virtual)

Latest Developments

More

Vaxart Announces FDA Clearance Of IND Application For Oral COVID-19 Vaccine

Vaxart Reports Q2 Loss Per Share Of $0.12

Vaxart Inc - Estimates Cash And Cash Equivalents, As Of June 30, 2020, Will Be About $44.4 Mln

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Vaxart Inc

Vaxart, Inc., formerly Aviragen Therapeutics, Inc., is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The Company has three product candidates in clinical development that address viral infections that have limited therapeutic options. Its products include vapendavir, an oral treatment for human rhinovirus (HRV) upper respiratory infections in moderate-to-severe asthmatics in Phase IIb SPIRITUS trial; BTA585, an oral fusion (F) protein inhibitor in Phase II development for the treatment and prevention of respiratory syncytial virus (RSV) infections, and BTA074, a topical antiviral treatment in Phase II development for condyloma caused by human papillomavirus Types 6 and 11. It has preclinical RSV non-fusion inhibitor program. It has focused its research and drug development capabilities on discovering and developing small molecule compounds that can prevent or treat infectious diseases.

Industry

Biotechnology & Drugs

Contact Info

385 Oyster Point Boulevard, Suite 9A

SOUTH SAN FRANCISCO, CA

94080

United States

+1.650.5503500

https://vaxart.com/

Executive Leadership

Wouter W. Latour

Chairman of the Board

Andrei Floroiu

Chief Executive Officer, Principal Financial Officer, Director

Margaret A. Echerd

Principal Accounting Officer, Vice President, Controller

Sean N. Tucker

Chief Scientific Officer

Robert A. Yedid

Lead Independent Director

Key Stats

2.00 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-0.069

2019

-0.860

2020(E)

-0.350
Price To Earnings (TTM)
--
Price To Sales (TTM)
111.79
Price To Book (MRQ)
19.07
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-53.22
Return on Equity (TTM)
-43.26

Latest News

Latest News

BRIEF-Vaxart Inc Files For Potential Mixed Shelf Offering- SEC Filing

* VAXART INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING

BRIEF-Vaxart Inc - Estimates Cash And Cash Equivalents, As Of June 30, 2020, Will Be About $44.4 Mln

* VAXART INC - ESTIMATES CASH AND CASH EQUIVALENTS, AS OF JUNE 30, 2020, WILL BE ABOUT $44.4 MILLION Source text: https://bit.ly/2DpIpiB Further company coverage:

Vaxart says potential COVID-19 vaccine picked for 'Operation Warp Speed'

Vaxart Inc said on Friday it would test its experimental oral COVID-19 vaccine on monkeys infected with the new coronavirus in a study funded by the Trump administration's vaccine-acceleration program called "Operation Warp Speed".

BRIEF-Vaxart’S Covid-19 Vaccine Selected For The U.S. Government’S Operation Warp Speed

* VAXART’S COVID-19 VACCINE SELECTED FOR THE U.S. GOVERNMENT’S OPERATION WARP SPEED

BRIEF-Vaxart Signs Memorandum Of Understanding With Attwill Medical Solutions Sterilflow,

* VAXART, INC. SIGNS MEMORANDUM OF UNDERSTANDING WITH ATTWILL MEDICAL SOLUTIONS STERILFLOW, LP

BRIEF-Vaxart Inc Set To Join Russell 3000 Index

* VAXART, INC. SET TO JOIN RUSSELL 3000® INDEX Source text for Eikon: Further company coverage:

BRIEF-Vaxart - Received Letter From Nasdaq Noting That Co Was Not In Compliance With Requirement Of Certain Listing Rule

* VAXART - ON JUNE 22, RECEIVED LETTER FROM NASDAQ NOTING THAT CO WAS NOT IN COMPLIANCE WITH REQUIREMENT OF CERTAIN LISTING RULE Source text for Eikon: https://bit.ly/3dumG5l Further company coverage:

BRIEF-Vaxart Appoints New CEO To Accelerate Advancement Of COVID-19 And Other Programs

* VAXART, INC. APPOINTS NEW CEO TO ACCELERATE ADVANCEMENT OF COVID-19 AND OTHER PROGRAMS

BRIEF-Armistice Capital Reports 19.99% Stake In Vaxart As Of June 2 - SEC Filing

* ARMISTICE CAPITAL LLC REPORTS 19.99% STAKE IN VAXART INC AS OF JUNE 2 - SEC FILING

BRIEF-Kindred Biosciences Reports Covid-19 Vaccine Manufacturing Agreement With Vaxart

* KINDRED BIOSCIENCES ANNOUNCES COVID-19 VACCINE MANUFACTURING AGREEMENT WITH VAXART

BRIEF-Armistice Capital Reports 14% Stake In Vaxart As Of May 11

* ARMISTICE CAPITAL, LLC REPORTS 14.0 % STAKE IN VAXART AS OF MAY 11, 2020 - SEC FILING

BRIEF-Vaxart Quarterly Loss Per Share $0.02

* VAXART ANNOUNCES FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Vaxart Announces Positive Pre-Clinical Data For Its Oral Covid-19 Vaccine Program

* VAXART ANNOUNCES POSITIVE PRE-CLINICAL DATA FOR ITS ORAL COVID-19 VACCINE PROGRAM Source text for Eikon: Further company coverage:

BRIEF-Vaxart Provides Update On Its Oral Covid-19 Vaccine Program

* VAXART PROVIDES UPDATE ON ITS ORAL COVID-19 VACCINE PROGRAM

BRIEF-Vaxart Reports Q4 Revenue Of $3.9 Mln

* VAXART ANNOUNCES FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Vaxart - Entered Agreement With Emergent Biosolutions For Development Of Oral Coronavirus Vaccine Candidate

* VAXART ANNOUNCES IT ENTERED INTO AN AGREEMENT WITH EMERGENT BIOSOLUTIONS FOR THE DEVELOPMENT AND MANUFACTURING OF ORAL CORONAVIRUS (COVID-19) VACCINE CANDIDATE Source text for Eikon: Further company coverage:

BRIEF-Vaxart Announces $10.0 Million Registered Direct Offering Priced At-The-Market

* VAXART ANNOUNCES $10.0 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET

BRIEF-Vaxart Appoints Dr. David Taylor As Chief Medical Officer

* VAXART APPOINTS DR. DAVID TAYLOR AS CHIEF MEDICAL OFFICER Source text for Eikon: Further company coverage:

BRIEF-Vaxart Announces $5 Mln Inavir Revenue Milestone

* VAXART - NOTIFIED BY DAIICHI SANKYO CO THAT SALES OF INAVIR EXCEEDED ¥20 BILLION IN FISCAL YEAR 2017, TRIGGERING A $5 MILLION MILESTONE PAYMENT TO CO

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up